Lumigan: Advanced Ophthalmic Solution for Glaucoma Management
Lumigan
| Product dosage: 0.03mg | |||
|---|---|---|---|
| Package (num) | Per bottle | Price | Buy |
| 1 | 62.01 $ | 62.01 $ (0%) | 🛒 Add to cart |
| 2 | 59.08 $ | 124.02 $ 118.17 $ (5%) | 🛒 Add to cart |
| 3 | 58.50 $ | 186.03 $ 175.50 $ (6%) | 🛒 Add to cart |
| 4 | 58.21 $ | 248.04 $ 232.83 $ (6%) | 🛒 Add to cart |
| 5 | 57.80 $ | 310.05 $ 288.99 $ (7%) | 🛒 Add to cart |
| 6 | 57.72 $ | 372.06 $ 346.32 $ (7%) | 🛒 Add to cart |
| 7 | 57.50 $ | 434.07 $ 402.48 $ (7%) | 🛒 Add to cart |
| 8 | 57.48 $ | 496.08 $ 459.81 $ (7%) | 🛒 Add to cart |
| 9 | 57.46 $ | 558.09 $ 517.14 $ (7%) | 🛒 Add to cart |
| 10 | 57.33 $
Best per bottle | 620.10 $ 573.30 $ (8%) | 🛒 Add to cart |
Synonyms | |||
Lumigan (bimatoprost ophthalmic solution) 0.01% is a prescription medication specifically formulated to reduce elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension. As a prostaglandin analog, it offers a targeted mechanism of action that enhances uveoscleral outflow, providing consistent and effective IOP control. This first-line treatment is renowned for its efficacy, tolerability, and once-daily dosing convenience, making it a cornerstone in modern glaucoma therapy protocols. Clinicians trust Lumigan for its well-established safety profile and demonstrated ability to preserve visual function over the long term.
Features
- Contains bimatoprost 0.01% as the active pharmaceutical ingredient
- Preservative-free formulation in single-use containers available
- pH-balanced solution compatible with ocular tissues
- Clear, isotonic ophthalmic solution
- Packaged in 2.5mL and 5mL sterile bottles with controlled-drop tip
- Stable at room temperature (15-25°C)
- Manufactured under strict pharmaceutical quality standards
Benefits
- Significantly reduces intraocular pressure by approximately 25-33% from baseline
- Provides 24-hour IOP control with once-daily administration
- Helps slow progression of glaucoma and preserve visual field
- Minimal systemic absorption reduces risk of systemic side effects
- Convenient dosing schedule improves patient adherence
- Compatible with other topical ophthalmic medications when properly timed
Common use
Lumigan is primarily indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension. It is typically prescribed as monotherapy but may be used concomitantly with other intraocular pressure-lowering medications when additional IOP reduction is required. The medication is suitable for long-term management of chronic ocular hypertension conditions and is often selected as first-line therapy due to its efficacy and favorable side effect profile compared to other medication classes.
Dosage and direction
The recommended dosage is one drop in the affected eye(s) once daily in the evening. Patients should remove contact lenses before instillation and wait at least 15 minutes before reinserting. To administer: wash hands thoroughly, tilt head backward, pull down lower eyelid to create a pouch, instill one drop, close eye gently, and apply light pressure to the lacrimal sac for one minute to minimize systemic absorption. Do not touch dropper tip to any surface to avoid contamination. If using other eye medications, allow at least 5 minutes between applications.
Precautions
Patients should be advised that Lumigan may gradually increase brown pigmentation of the iris, which may be permanent. Eyelid skin darkening may occur and may be reversible upon discontinuation. There may be gradual changes to eyelashes and vellus hair in the treated eye, including increased length, thickness, and darkness. Use with caution in patients with intraocular inflammation, aphakic patients, pseudophakic patients with torn posterior lens capsule, or patients with known risk factors for macular edema. Patients should be monitored for bacterial keratitis associated with multiple-use containers.
Contraindications
Lumigan is contraindicated in patients with hypersensitivity to bimatoprost or any component of the formulation. Should not be used in patients with active intraocular inflammation unless the potential benefits outweigh the risks. Not recommended for use in pediatric patients as safety and effectiveness have not been established. Contraindicated in patients with angle-closure glaucoma unless accompanied by appropriate iridectomy.
Possible side effects
Most common ocular side effects include conjunctival hyperemia (15-45%), growth of eyelashes (30-50%), ocular pruritus (approximately 15%), and ocular dryness (10-15%). Less frequently reported effects include visual disturbance, ocular burning, foreign body sensation, eye pain, pigmentation of the periocular skin, blepharitis, cataract, superficial punctate keratitis, eyelid erythema, ocular irritation, and eyelash darkening. Iris pigmentation changes occur gradually and may not be noticeable for months to years. Serious but rare side effects include macular edema, uveitis, and herpes simplex keratitis.
Drug interaction
Although minimal systemic absorption occurs, potential interactions include concomitant use with other prostaglandin analogs may reduce additional IOP-lowering effect. No clinically significant interactions with systemic medications have been established. However, patients using eye drops containing thimerosal should space administration至少5 minutes apart as precipitation may occur. Caution advised when using with other medications that may affect intraocular pressure.
Missed dose
If a dose is missed, patients should instill the drop as soon as possible. However, if it is almost time for the next scheduled dose, skip the missed dose and resume the regular dosing schedule. Do not instil two drops to make up for a missed dose. Maintain the once-daily regimen without doubling the dosage. Consistent evening administration helps maintain stable intraocular pressure control.
Overdose
Ocular overdose may be flushed from the eye(s) with warm tap water. Systemic absorption following ocular administration is minimal, making systemic toxicity unlikely. If accidentally ingested, symptomatic treatment should be provided. In case of ocular overdose, monitor for increased ocular irritation and hyperemia. No specific antidote exists; treatment should be symptomatic and supportive. Medical attention should be sought if accidental ingestion occurs, especially in children.
Storage
Store at room temperature between 15°C to 25°C (59°F to 77°F). Protect from light. Keep container tightly closed when not in use. Do not freeze. Discard any unused solution 28 days after first opening the bottle. Single-use containers should be used immediately after opening and any unused portion discarded. Keep out of reach of children and pets. Do not use if solution changes color or becomes cloudy.
Disclaimer
This information is for educational purposes only and does not replace professional medical advice. Lumigan is a prescription medication that should be used only under the supervision of a qualified healthcare provider. Patients should not adjust dosage or discontinue treatment without consulting their ophthalmologist. The complete prescribing information should be consulted before initiating therapy. Individual results may vary based on patient-specific factors and disease severity.
Reviews
Clinical studies demonstrate Lumigan’s consistent efficacy in intraocular pressure reduction, with mean IOP reductions of 7-8 mmHg observed across multiple trials. Ophthalmologists report high satisfaction with its predictable response and patient tolerance profile. Patients appreciate the once-daily dosing convenience, though some note initial ocular irritation that typically diminishes with continued use. Long-term studies confirm maintained efficacy over 24 months of treatment with stable safety profile. Real-world evidence supports its position as a first-line therapy for open-angle glaucoma management.